Document is current
Any future updates will be listed below
-
Authors
Swearingen, Christopher J.
Tambiah, Jeyanesh R. S.
Simsek, Ismail
Ghandehari, Heli
Kennedy, Sarah
Yazici, Yusuf
-
Funding
Funding for this research was provided by:
Biosplice Therapeutics, Inc
- License Information
-
More Information
Article History
Received: 15 July 2024
Accepted: 18 November 2024
First Online: 4 January 2025
Declarations
:
: Christopher Swearingen, Jeyanesh Tambiah, Ismail Simsek, Heli Ghandehari, Sarah Kennedy and Yusuf Yazici are/were employees and shareholders of Biosplice Therapeutics, Inc.
: All studies were conducted in accordance with the Declaration of Helsinki, the International Conference for Harmonisation Good Clinical Practice Guidelines, and applicable regulations. The trial was conducted under institutional review board approval, primarily by Advarra IRB (a full list of IRBs is provided in the Supplementary Methods). All patients provided informed consent prior to participating in any trial-related procedures.
